Bronchiolitis Clinical Trial
— EPINIR-BRONOfficial title:
EPINIR-BRONCHIO : Evaluation Pragmatique de l'Impact du NIrsevimab Sur le Recours Aux uRgences Pour BRONCHIOlite Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
Verified date | December 2023 |
Source | Hôpital Armand Trousseau |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In July 2023, the Food and Drug Administration approved nirsevimab (Beyfortus®), a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection (Bronchiolitis) among infants and young children. In Europe, The European Medicines Agency approved the use of BEYFORTUS in October 2022. In France, The Haute Autorité de Santé (HAS) approved the use of BEYFORTUS in July 2023 starting in September 2023. Beyfortus is administered as a single intramuscular injection prior to or during RSV season. This single dose may provide protection during the whole RSV season. The safety and efficacy of Beyfortus® were supported by three clinical trials (1-3). The key measure of efficacy was the incidence of medically attended RSV lower respiratory tract infection (MA RSV LRTI ) evaluated during the 150 days after Beyfortus® administration. Beyfortus® reduced the risk of MA RSV LRTI by approximately 70% to 75% relative to placebo. The objective of this observational study is to assess in the real-world the effectiveness of nirsevimab on the Emergency Department use for bronchiolitis as well on the effectiveness of nirsevimab to reduce hospitalization and healthcare usage in France where a national campaign to administer nirsevimab to young infants stated on September 14th, 2023. Type of study Retrospective observational study of medical records which include systematic and prospective data on nirsevimab immunization status of patients visiting the Emergency Department. Methodology This retrospective observational study will include two data set analysis. On one part, data from all infants presenting to the emergency department and diagnosed as having bronchiolitis will be retrieved from medical and nursing records and those who had been given nirsevimab will be compared with those who did not receive this medication prior to the ED visit. On the other part, since the investigators have included nirsevimab administration in their systematic data collection on immunization of all infants visiting our ED, the investigators will use the nirsevimab immunization status of infants diagnosed as having bronchiolitis with those do not having bronchiolitis in order to assess the effectiveness (real-world effect) of nirsevimab on the ED use and hospitalization.
Status | Recruiting |
Enrollment | 6000 |
Est. completion date | February 29, 2024 |
Est. primary completion date | February 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Day to 2 Years |
Eligibility | Inclusion Criteria: - All infants aged 1 year or youger visiting the emergecy department - All bronchiolitis visiting the emergency department during the 2023-2024 season Exclusion Criteria: -None |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Armand Trousseau | Paris |
Lead Sponsor | Collaborator |
---|---|
Hôpital Armand Trousseau |
France,
Domachowske J, Madhi SA, Simoes EAF, Atanasova V, Cabanas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186. No abstract available. — View Citation
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simoes EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. Erratum In: N Engl J Med. 2020 Aug 13;383(7):698. — View Citation
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wahlby Hamren U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Real-world effectiveness of nirsevimab to reduce emergency use for bronchiolitis | Determination of the nirsevimab effectiveness by using the screening method and the negative-test design | Bronchiolitis season: Octobre 2023-February 2024 | |
Primary | Hospital resources usage of bronchiolitis patients with and without previous administration of nirsevimab | Infants presenting bronchiolitis and having received nirsevimab will be compared to those who did not receive this medication. | Bronchiolitis season: Octobre 2023-February 2024 | |
Secondary | Age distribution of bronchiolitis patients visiting the ermergency department during the 2023-2024, 2022-2023 and 2019-2020 seasons | Compared the age distributions of two previous bronchiolitis seasons with the present season to see if the use of nirsevimab has changed this age distribution. | Bronchiolitis season: Octobre 2023-February 2024 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04989114 -
Nasal Bubble Continuous Positive Airway Pressure in Reducing Respiratory Distress in Children With Bronchiolitis
|
N/A | |
Recruiting |
NCT06016244 -
Safe, Effective and Cost-Effective Oxygen Saturation Targets for Children and Adolescents With Respiratory Distress: a Randomized Controlled Trial
|
N/A | |
Not yet recruiting |
NCT05902702 -
Isotonic Saline for Children With Bronchiolitis
|
N/A | |
Recruiting |
NCT02366715 -
Treatment Of Bronchiolitis With Heated Humidified High Flow Nasal Cannula - Prospective And Retrospective Research
|
Phase 3 | |
Terminated |
NCT02219334 -
Comparing Nasal Suction Devices in Children With Bronchiolitis: A Pilot Study
|
N/A | |
Recruiting |
NCT01944995 -
Work of Breathing in Nasal CPAP Versus High Flow Nasal Prong in Infants With Severe Acute Bronchiolitis
|
N/A | |
Terminated |
NCT02834819 -
Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis
|
N/A | |
Terminated |
NCT01757496 -
Cough Assist in Bronchiolitis
|
N/A | |
Not yet recruiting |
NCT01414322 -
Documentation of Continuous Wheeze and Cough Dynamics in Pediatric ER SOB Patients
|
N/A | |
Completed |
NCT00369759 -
An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants
|
N/A | |
Completed |
NCT00347880 -
Atrial and Brain Natriuretic Peptides in Bronchiolitis
|
Phase 1 | |
Recruiting |
NCT05548036 -
A Feasibility RCT of Aerobika Verses ACBT in People With COPD
|
N/A | |
Active, not recruiting |
NCT04302207 -
The ROUTT-B (Reduce Over-Utilized Tests and Treatments in Bronchiolitis) Study
|
N/A | |
Completed |
NCT02858531 -
Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
|
||
Withdrawn |
NCT05994183 -
The Bronchiolitis in Hospitalized Infants Study
|
Early Phase 1 | |
Terminated |
NCT03614507 -
Automation Oxygen Flow Titration in Spontaneously Breathing Infants
|
N/A | |
Completed |
NCT02856165 -
High-flow Nasal Oxygen Therapy in Hospitalized Infant With Moderate-to-severe Bronchiolitis
|
N/A | |
Recruiting |
NCT05909566 -
Respiratory Support and Treatment for Efficient and Cost-Effective Care
|
N/A | |
Recruiting |
NCT04437641 -
Impact of Pediatrician Intervention on the Smoking Habits of Parents of Sick Children
|
||
Not yet recruiting |
NCT06083077 -
Chest and Abdominal Wall Strapping in Infant With Bronchiolitis
|
N/A |